论文部分内容阅读
目前人们对血吸虫病相关性肺动脉高压发病机制不甚清楚;治疗上缺乏针对性用药。一些靶向治疗药物如磷酸二酯酶-5抑制剂及酪氨酸酶抑制剂价格昂贵,对那些资源匮乏的血吸虫病地区,经济上无法承受。同时治疗肺动脉高压的药物理论上在血吸虫性肺动脉高压中可使患者受益,但仍缺乏循证医学证据,其安全性、有效性、依从性及给药途径方面存在一定的限制。本文旨在描述血吸虫病相关性肺动脉高压的发病机制、治疗及预后。
At present, people are not clear about the pathogenesis of schistosomiasis-related pulmonary hypertension; the treatment is lack of targeted medication. Some targeted therapies such as phosphodiesterase-5 inhibitors and tyrosinase inhibitors are expensive and economically unaffordable in those resource-poor areas of schistosomiasis. At the same time, the drugs that treat pulmonary hypertension at the same time can theoretically benefit patients with schistosomiasis pulmonary hypertension, but there is still a lack of evidence of evidence-based medicine. The safety, efficacy, compliance and route of administration have some limitations. This article aims to describe the pathogenesis, treatment and prognosis of schistosomiasis-related pulmonary hypertension.